HIF1A and urinary bladder cancer: FDA approved topoisomerase inhibitor topotecan may affect HIF1A and is being used in the treatment of other forms of cancer such as lung, ovarian and cervical cancer and therefore may be suitable for repurposing for the treatment of bladder cancer.